ICCC
Price
$5.50
Change
-$0.00 (-0.00%)
Updated
Apr 28 closing price
Capitalization
49.47M
15 days until earnings call
MYNDF
Price
$0.01
Change
-$0.05 (-83.33%)
Updated
Mar 25 closing price
Capitalization
2.41M
Ad is loading...

ICCC vs MYNDF

Header iconICCC vs MYNDF Comparison
Open Charts ICCC vs MYNDFBanner chart's image
ImmuCell
Price$5.50
Change-$0.00 (-0.00%)
Volume$14.36K
Capitalization49.47M
MYND Life Sciences
Price$0.01
Change-$0.05 (-83.33%)
Volume$30K
Capitalization2.41M
ICCC vs MYNDF Comparison Chart
Loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ICCC vs. MYNDF commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Buy and MYNDF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (ICCC: $5.50 vs. MYNDF: $0.01)
Brand notoriety: ICCC and MYNDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICCC: 62% vs. MYNDF: 172%
Market capitalization -- ICCC: $49.47M vs. MYNDF: $2.41M
ICCC [@Biotechnology] is valued at $49.47M. MYNDF’s [@Biotechnology] market capitalization is $2.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $272.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICCC’s FA Score shows that 0 FA rating(s) are green whileMYNDF’s FA Score has 1 green FA rating(s).

  • ICCC’s FA Score: 0 green, 5 red.
  • MYNDF’s FA Score: 1 green, 4 red.
According to our system of comparison, both ICCC and MYNDF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 6 TA indicator(s) are bullish.

  • ICCC’s TA Score: 6 bullish, 3 bearish.

Price Growth

ICCC (@Biotechnology) experienced а +2.23% price change this week, while MYNDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.96%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -9.88%.

Reported Earning Dates

ICCC is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+7.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICCC($49.5M) has a higher market cap than MYNDF($2.41M). ICCC YTD gains are higher at: 6.796 vs. MYNDF (-82.425). MYNDF has higher annual earnings (EBITDA): -273.7K vs. ICCC (-551.81K). ICCC has more cash in the bank: 3.81M vs. MYNDF (1.81K). MYNDF has less debt than ICCC: MYNDF (3M) vs ICCC (15.5M). ICCC has higher revenues than MYNDF: ICCC (23.8M) vs MYNDF (1).
ICCCMYNDFICCC / MYNDF
Capitalization49.5M2.41M2,054%
EBITDA-551.81K-273.7K202%
Gain YTD6.796-82.425-8%
P/E RatioN/AN/A-
Revenue23.8M12,380,000,000%
Total Cash3.81M1.81K210,791%
Total Debt15.5M3M517%
FUNDAMENTALS RATINGS
ICCC: Fundamental Ratings
ICCC
OUTLOOK RATING
1..100
34
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
84
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ICCC
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 26 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Ad is loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JERCX11.11N/A
N/A
Janus Henderson Global Real Estate C
HBGIX20.88N/A
N/A
Hartford Disciplined Equity HLS IB
JHCPX14.19N/A
N/A
JHFunds2 Capital Appreciation NAV
RMBMX11.59N/A
N/A
RMB SMID Cap I
TRZAX44.72N/A
N/A
T. Rowe Price Value Z

ICCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
N/A
NKTX - ICCC
43%
Loosely correlated
-4.74%
ATHE - ICCC
27%
Poorly correlated
-0.02%
BOLT - ICCC
26%
Poorly correlated
-5.08%
IMMP - ICCC
23%
Poorly correlated
+1.23%
MYNDF - ICCC
23%
Poorly correlated
N/A
More

MYNDF and

Correlation & Price change

A.I.dvisor tells us that MYNDF and NERV have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MYNDF and NERV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYNDF
1D Price
Change %
MYNDF100%
N/A
NERV - MYNDF
29%
Poorly correlated
+1.70%
ICCC - MYNDF
23%
Poorly correlated
N/A
CSBR - MYNDF
20%
Poorly correlated
-7.47%
AEON - MYNDF
7%
Poorly correlated
-2.42%
INKT - MYNDF
4%
Poorly correlated
-2.60%
More